Payers Like Biosimilars, But Rebates Remain The Bottom Line (For Now)
Executive Summary
The US launch of Pfizer's Inflectra has been an early case study for the US biosimilar market, and some biosimilar manufacturers and payers say market access challenges are worrying.
You may also be interested in...
Payers Could Guarantee Biosimilar Market Share, FDA's Gottlieb Suggests
Commissioner worries that fewer drugs may enter market in some categories because of drug development costs, and offers some post-market strategies for encouraging biosimilar development.
Pfizer Sets The Stage For A Biosimilar Showdown Over Exclusive Contracts
Pfizer filed a lawsuit against J&J over its efforts to block sales of Pfizer's biosimilar Inflectra through exclusive contracting for Remicade. The suit claims J&J coerced payers by vowing to withhold all Remicade rebates if any Inflectra is reimbursed. J&J says Pfizer has failed to show the value of Inflectra.
Merck's Second-To-Market Renflexis Biosimilar Priced Below The First
Merck & Co. launched Renflexis in the US, marking the first time two biosimilars will compete for share against a brand, in this case J&J's Remicade.